Finally, we showed, in a resistant syngeneic murine NB model, a significant improvement in the antitumor efficacy of the chimeric anti-GD2 Ab DB against NB by the additional blockade of the immune checkpoints TIGIT and PD-L1, providing an effective combinatorial treatment strategy against high-risk NB. Here, TIGIT is linked to neuroblastoma.